{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:26:41Z","timestamp":1790252801334,"version":"4.1.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,26]],"date-time":"2027-05-26T00:00:00Z","timestamp":1811289600000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001446"],"award-info":[{"award-number":["KL2TR001446"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017815","name":"American College of Chest Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R35 HL144805"],"award-info":[{"award-number":["R35 HL144805"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005640","name":"Flight Attendant Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003442","name":"Stony Wold Herbert Fund Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019743","name":"West Virginia Clinical and Translational Science Institute","doi-asserted-by":"publisher","award":["5TL1TR001447-09"],"award-info":[{"award-number":["5TL1TR001447-09"]}],"id":[{"id":"10.13039\/100019743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001540","name":"CHEST Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ccm.2025.12.018","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:48:03Z","timestamp":1769806083000},"page":"383-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions"],"prefix":"10.1016","volume":"47","author":[{"given":"Jezreel","family":"Pantale\u00f3n Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ccm.2025.12.018_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S1473-3099(24)00176-2","article-title":"Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"24","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/resp.14389","article-title":"Trends of global and regional aetiologies, risk factors and mortality of lower respiratory infections from 1990 to 2019: an analysis for the Global Burden of Disease Study 2019","volume":"28","author":"Kang","year":"2023","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib3","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2025.12.018_bib5","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2025.12.018_bib6","article-title":"Antimicrobial resistance: a concise update","author":"Ho","year":"2024","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1513\/AnnalsATS.202102-209ST","article-title":"Understanding the host in the management of pneumonia. an official american thoracic society workshop report","volume":"18","author":"Dela Cruz","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00168-19","article-title":"Host-directed antiviral therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib10","doi-asserted-by":"crossref","first-page":"AID-0026","DOI":"10.1128\/microbiolspec.AID-0026-2014","article-title":"History and practice: antibodies in infectious diseases","volume":"3","author":"Hey","year":"2015","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ccm.2025.12.018_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.blo.0000183429.83168.07","article-title":"The CLASSIC: penicillin as a chemotherapeutic agent. 1940","volume":"439","author":"Chain","year":"2005","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ccm.2025.12.018_bib12","unstructured":"Antibiotic resistance threats in the United States, 2019. Report. 2019."},{"issue":"Suppl 2","key":"10.1016\/j.ccm.2025.12.018_bib13","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","article-title":"Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria","volume":"54","author":"Mauldin","year":"2010","journal-title":"Antimicrob Agents Ch"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1183\/09031936.00188313","article-title":"Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement","volume":"44","author":"Lange","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/femsre\/fux011","article-title":"Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives","volume":"41","author":"Gygli","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"10","key":"10.1016\/j.ccm.2025.12.018_bib17","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1016\/S2214-109X(23)00369-8","article-title":"Costs incurred by people receiving tuberculosis treatment in low-income and middle-income countries: a meta-regression analysis","volume":"11","author":"Portnoy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ccm.2025.12.018_bib18","series-title":"WHO fungal priority pathogens list to guide research, development and public health action","author":"Organization","year":"2022"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib19","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ccm.2025.12.018_bib20","first-page":"1","article-title":"Invasive aspergillosis and the impact of azole-resistance","author":"Bosetti","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"issue":"15","key":"10.1016\/j.ccm.2025.12.018_bib21","first-page":"1248","article-title":"CDC: candida auris fungal infections and drug resistance on the rise","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1513\/AnnalsATS.202212-1019ST","article-title":"Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American thoracic society workshop report","volume":"20","author":"Cheng","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02287-16","article-title":"Bacterial topography of the healthy human lower respiratory tract","volume":"8","author":"Dickson","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ccm.2025.12.018_bib24","article-title":"Episodic aspiration with oral commensals induces a MyD88-dependent, pulmonary Th17 response that mitigates susceptibility to streptococcus pneumoniae","author":"Wu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2025.12.018_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2016.31","article-title":"Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Article","author":"Segal","year":"2016","journal-title":"Nat Microbiol"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.medj.2020.11.003","article-title":"Tuberculosis endotypes to guide stratified host-directed therapy","volume":"2","author":"DiNardo","year":"2021","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02263-2021","article-title":"Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes","volume":"60","author":"DiNardo","year":"2022","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ccm.2025.12.018_bib28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/thoraxjnl-2016-209719","article-title":"Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis","volume":"72","author":"Bos","year":"2017","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13054-021-03755-7","article-title":"Identification of persistent and resolving subphenotypes of acute hypoxemic respiratory failure in two independent cohorts","volume":"25","author":"Sathe","year":"2021","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib30","first-page":"671","article-title":"Hydrocortisone in severe community-acquired pneumonia. reply","volume":"389","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2025.12.018_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","article-title":"Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)","volume":"44","author":"Welte","year":"2018","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s13054-023-04719-9","article-title":"The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial","volume":"27","author":"Singer","year":"2023","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib33","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41467-022-29353-x","article-title":"Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics","volume":"13","author":"Ramachandran","year":"2022","journal-title":"Nat Commun"},{"issue":"52","key":"10.1016\/j.ccm.2025.12.018_bib34","doi-asserted-by":"crossref","first-page":"E12353","DOI":"10.1073\/pnas.1809700115","article-title":"Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults","volume":"115","author":"Langelier","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib35","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-024-02999-4","article-title":"Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation","volume":"30","author":"Zinter","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ccm.2025.12.018_bib36","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.2020009246","article-title":"The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury","volume":"137","author":"Zinter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccm.2025.12.018_bib37","article-title":"Empiric azithromycin in COVID-19 impacts the respiratory microbiome and antimicrobial resistome without anti-inflammatory benefit","author":"Langelier","year":"2025","journal-title":"Res Sq"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/QCO.0b013e32835ebc6d","article-title":"Long-term prognosis in community-acquired pneumonia","volume":"26","author":"Restrepo","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"7554","key":"10.1016\/j.ccm.2025.12.018_bib39","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.ccm.2025.12.018_bib40","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ccm.2025.12.018_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/archinte.159.9.970","article-title":"Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study","volume":"159","author":"Fine","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146318","article-title":"Circulating angiogenic factors as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis","volume":"11","author":"Kumar","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ccm.2025.12.018_bib43","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300332","article-title":"Adjunctive N-acetylcysteine and lung function in pulmonary tuberculosis","volume":"3","author":"Wallis","year":"2024","journal-title":"NEJM Evid"},{"issue":"8","key":"10.1016\/j.ccm.2025.12.018_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"21","key":"10.1016\/j.ccm.2025.12.018_bib45","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib46","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","article-title":"2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia","volume":"52","author":"Chaudhuri","year":"2024","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccm.2025.12.018_bib47","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","article-title":"Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia","volume":"48","author":"Meduri","year":"2022","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ccm.2025.12.018_bib49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.chom.2017.03.003","article-title":"Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-drug-treated HIV patients","volume":"21","author":"Segal","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib50","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1038\/s41467-022-31074-0","article-title":"Airway Prevotella promote TLR2-dependent neutrophil activation and rapid clearance of Streptococcus pneumoniae from the lung","volume":"13","author":"Horn","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1165\/rcmb.2008-0260OC","article-title":"Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi","volume":"42","author":"Evans","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"10.1016\/j.ccm.2025.12.018_bib52","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood-2016-03-708511","article-title":"Inducible epithelial resistance protects mice against leukemia-associated pneumonia","volume":"128","author":"Leiva-Juarez","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.04061-24","article-title":"Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis","volume":"16","author":"Pantaleon Garcia","year":"2025","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01584-2020","article-title":"TLR2-mediated innate immune priming boosts lung anti-viral immunity","volume":"58","author":"Girkin","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.mucimm.2024.02.010","article-title":"The bacterial lysate OM-85 engages toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cells","volume":"17","author":"Khameneh","year":"2024","journal-title":"Mucosal Immunol"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003727","article-title":"Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung","volume":"9","author":"LeMessurier","year":"2013","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1189\/jlb.4A1215-581R","article-title":"Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia","volume":"101","author":"Shindo","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/SHK.0000000000001919","article-title":"Contribution of IL-38 in lung immunity during pseudomonas aeruginosa-induced pneumonia","volume":"57","author":"Wei","year":"2022","journal-title":"Shock"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib59","article-title":"Serum IL-17A and IL-6 in paediatric Mycoplasma pneumoniae pneumonia: implications for different endotypes","volume":"13","author":"Wang","year":"2024","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.ccm.2025.12.018_bib60","article-title":"Role of interleukin-17 in a murine community-associated methicillin-resistant Staphylococcus aureus pneumonia model","author":"Shibue","year":"2018","journal-title":"Microb Infect"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007099","article-title":"IL-17 can be protective or deleterious in murine pneumococcal pneumonia","volume":"14","author":"Ritchie","year":"2018","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib62","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41385-020-0273-y","article-title":"IL-17 production by tissue-resident MAIT cells is locally induced in children with pneumonia","volume":"13","author":"Lu","year":"2020","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaci.2018.03.007","article-title":"IL-17-producing ST2(+) group 2 innate lymphoid cells play a pathogenic role in lung inflammation","volume":"143","author":"Cai","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jleuko\/qiad070","article-title":"Neutrophil responsiveness to IL-10 impairs clearance of Streptococcus pneumoniae from the lungs","volume":"115","author":"Horn","year":"2024","journal-title":"J Leukoc Biol"},{"issue":"22","key":"10.1016\/j.ccm.2025.12.018_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310864121","article-title":"IL-33 controls IL-22-dependent antibacterial defense by modulating the microbiota","volume":"121","author":"Rowekamp","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib66","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.4049\/jimmunol.175.11.7530","article-title":"Lung NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia","volume":"175","author":"Jones","year":"2005","journal-title":"J Immunol"},{"issue":"Pt 1","key":"10.1016\/j.ccm.2025.12.018_bib67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1099\/jmm.0.45736-0","article-title":"Compensatory response of IL-1 gene knockout mice after pulmonary infection with Klebsiella pneumoniae","volume":"54","author":"Tanabe","year":"2005","journal-title":"J Med Microbiol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib68","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41467-017-01803-x","article-title":"The microbiota protects against respiratory infection via GM-CSF signaling","volume":"8","author":"Brown","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib69","doi-asserted-by":"crossref","first-page":"L447","DOI":"10.1152\/ajplung.00415.2010","article-title":"TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia","volume":"302","author":"Standiford","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.ccm.2025.12.018_bib70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib71","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI23949","article-title":"Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production","volume":"115","author":"Bafica","year":"2005","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib72","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cell.2010.02.013","article-title":"The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans","volume":"140","author":"Tobin","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib73","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4103\/0028-3886.246278","article-title":"Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?","volume":"66","author":"Misra","year":"2018","journal-title":"Neurol India"},{"key":"10.1016\/j.ccm.2025.12.018_bib74","article-title":"Antitubercular potential and pH-driven mode of action of salicylic acid derivatives","author":"Laudouze","year":"2024","journal-title":"FEBS Open Bio"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis","volume":"208","author":"Vilaplana","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib77","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1038\/s41467-021-27029-6","article-title":"A Phase I\/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients","volume":"12","author":"Jenum","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017091","article-title":"Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice","volume":"6","author":"Koo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2025.12.018_bib79","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fimmu.2016.00238","article-title":"Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of mycobacterium tuberculosis","volume":"7","author":"Subbian","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.ccm.2025.12.018_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsbmb.2017.07.027","article-title":"Vitamin D, cod liver oil, sunshine, and phototherapy: safe, effective and forgotten tools for treating and curing tuberculosis infections - a comprehensive review","volume":"177","author":"McCullough","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib81","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/iai.57.3.840-844.1989","article-title":"Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages","volume":"57","author":"Crowle","year":"1989","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib82","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/infdis\/jiad460","article-title":"Adjunct therapy with all-trans-retinoic acid improves therapeutic efficacy through immunomodulation while treating tuberculosis with antibiotics in mice","volume":"229","author":"Singh","year":"2024","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib83","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.4049\/jimmunol.1301686","article-title":"All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2","volume":"192","author":"Wheelwright","year":"2014","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.ccm.2025.12.018_bib84","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1128\/iai.55.12.2945-2950.1987","article-title":"Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages","volume":"55","author":"Crowle","year":"1987","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.ccm.2025.12.018_bib85","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4049\/jimmunol.179.4.2060","article-title":"Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin","volume":"179","author":"Liu","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029631","article-title":"Vitamins A & D inhibit the growth of mycobacteria in radiometric culture","volume":"7","author":"Greenstein","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2025.12.018_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fmicb.2011.00067","article-title":"A novel in vitro human macrophage model to study the persistence of mycobacterium tuberculosis using vitamin D(3) and retinoic acid activated THP-1 macrophages","volume":"2","author":"Estrella","year":"2011","journal-title":"Front Microbiol"},{"issue":"24","key":"10.1016\/j.ccm.2025.12.018_bib88","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1097\/CM9.0000000000000554","article-title":"Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a meta-analysis of randomized controlled trials","volume":"132","author":"Zhang","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib89","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/infdis\/jiz064","article-title":"Metformin alters human host responses to mycobacterium tuberculosis in healthy subjects","volume":"220","author":"Lachmandas","year":"2019","journal-title":"J Infect Dis"},{"issue":"263","key":"10.1016\/j.ccm.2025.12.018_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.ccm.2025.12.018_bib91","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jdi.13523","article-title":"Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: a retrospective cohort study in a single teaching hospital","volume":"12","author":"Fu","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib92","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cid\/cix819","article-title":"Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment","volume":"66","author":"Degner","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11112298","article-title":"Impact of N-Acetyl Cysteine (NAC) on Tuberculosis (TB) patients-a systematic review","volume":"11","author":"Mapamba","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ccm.2025.12.018_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2018.12.008","article-title":"Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection","volume":"243","author":"Dwivedi","year":"2019","journal-title":"J Ethnopharmacol"},{"issue":"10","key":"10.1016\/j.ccm.2025.12.018_bib95","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.febslet.2006.03.071","article-title":"Suppression of Mycobacterium tuberculosis induced reactive oxygen species (ROS) and TNF-alpha mRNA expression in human monocytes by allicin","volume":"580","author":"Hasan","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ccm.2025.12.018_bib96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijid.2018.02.021","article-title":"Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis","volume":"69","author":"Rao","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"15","key":"10.1016\/j.ccm.2025.12.018_bib97","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0018-2016","article-title":"Cytokines and chemokines in mycobacterium tuberculosis infection","volume":"4","author":"Domingo-Gonzalez","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib99","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antibiotics9060312","article-title":"Candidiasis and mechanisms of antifungal resistance","volume":"9","author":"Bhattacharya","year":"2020","journal-title":"Antibiotics"},{"issue":"8","key":"10.1016\/j.ccm.2025.12.018_bib101","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3390\/jof8080805","article-title":"A fun-guide to innate immune responses to fungal infections","volume":"8","author":"Burgess","year":"2022","journal-title":"J Fungi"},{"key":"10.1016\/j.ccm.2025.12.018_bib102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12281-010-0034-6","article-title":"T-cell subsets and antifungal host defenses","volume":"4","author":"van de Veerdonk","year":"2010","journal-title":"Current fungal infection reports"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib103","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/infdis\/jiz692","article-title":"Trained immunity confers broad-spectrum protection against bacterial infections","volume":"222","author":"Ciarlo","year":"2020","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.ccm.2025.12.018_bib104","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1002\/eji.200323737","article-title":"Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection","volume":"33","author":"Netea","year":"2003","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2567.2009.03211.x","article-title":"Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity","volume":"130","author":"Chai","year":"2010","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib106","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/514027","article-title":"Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist","volume":"176","author":"Cenci","year":"1997","journal-title":"JID (J Infect Dis)"},{"key":"10.1016\/j.ccm.2025.12.018_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series","volume":"14","author":"Delsing","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib108","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/498981","article-title":"T cells require tumor necrosis factor\u2013\u03b1 to provide protective immunity in mice infected with histoplasma capsulatum","volume":"193","author":"Deepe","year":"2006","journal-title":"JID (J Infect Dis)"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib109","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1128\/IAI.05350-11","article-title":"Immunization with apoptotic phagocytes containing Histoplasma capsulatum activates functional CD8+ T cells to protect against histoplasmosis","volume":"79","author":"Hsieh","year":"2011","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib110","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.1501171","article-title":"CD43 functions as an E-selectin ligand for Th17 cells in vitro and is required for rolling on the vascular endothelium and Th17 cell recruitment during inflammation in vivo","volume":"196","author":"Vel\u00e1zquez","year":"2016","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcp.24430","article-title":"CD 43 signals prepare human T cells to receive cytokine differentiation signals","volume":"229","author":"Galindo-Albarr\u00e1n","year":"2014","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ccm.2025.12.018_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.595301","article-title":"The role of the interleukin-17 axis and neutrophils in the pathogenesis of endemic and systemic mycoses","volume":"10","author":"Puerta-Arias","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib113","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/imm.12953","article-title":"Helper T-cell responses and pulmonary fungal infections","volume":"155","author":"McDermott","year":"2018","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib114","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e2","article-title":"IL-17 and IL-21: their immunobiology and therapeutic potentials","volume":"24","author":"Koh","year":"2024","journal-title":"Immune Network"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006175","article-title":"Central role of IL-23 and IL-17 producing eosinophils as immunomodulatory effector cells in acute pulmonary aspergillosis and allergic asthma","volume":"13","author":"Guerra","year":"2017","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib116","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/pharmaceutics14030621","article-title":"LncRNA: a potential target for host-directed therapy of candida infection","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37236-4","article-title":"Discovery of long non-coding RNAs in Aspergillus flavus response to water activity, CO2 concentration, and temperature changes","volume":"13","author":"Davati","year":"2023","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib118","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/IAI.00507-12","article-title":"Titan cell production enhances the virulence of Cryptococcus neoformans","volume":"80","author":"Crabtree","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.ccm.2025.12.018_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147476","article-title":"Trained immunity: a \u201cnew\u201d weapon in the fight against infectious diseases","volume":"14","author":"Dagenais","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cei\/uxab014","article-title":"Targeting immunometabolism in host-directed therapies to fungal disease","volume":"208","author":"Gon\u00e7alves","year":"2022","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41581-022-00633-5","article-title":"Trained immunity - basic concepts and contributions to immunopathology","volume":"19","author":"Ochando","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ccm.2025.12.018_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.905867","article-title":"T cell responses to control fungal infection in an immunological memory lens","volume":"13","author":"Sharma","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib123","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chest.2023.10.005","article-title":"A diagnostic approach to fungal pneumonia: an infectious diseases perspective","volume":"165","author":"Azar","year":"2024","journal-title":"Chest"},{"issue":"664","key":"10.1016\/j.ccm.2025.12.018_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"Seif","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcyt.2020.11.002","article-title":"Glucuronoxylomannan in the Cryptococcus species capsule as a target for chimeric antigen receptor T-cell therapy","volume":"23","author":"da Silva","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ccm.2025.12.018_bib126","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3389\/fimmu.2019.01524","article-title":"Pathogenic fungal infection in the lung","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ccm.2025.12.018_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.718350","article-title":"NKT cells contribute to the control of microbial infections","volume":"11","author":"Vogt","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.chom.2011.09.011","article-title":"Innate recognition of cell wall \u03b2-glucans drives invariant natural killer T cell responses against fungi","volume":"10","author":"Cohen","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41467-018-03014-4","article-title":"Identification of the fungal ligand triggering cytotoxic PRR-mediated NK cell killing of Cryptococcus and Candida","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib130","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.4049\/jimmunol.1800085","article-title":"The TLR4 agonist monophosphoryl lipid A drives broad resistance to infection via dynamic reprogramming of macrophage metabolism","volume":"200","author":"Fensterheim","year":"2018","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.ccm.2025.12.018_bib131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib132","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ccm.2025.12.018_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108652","article-title":"Influenza infection, SARS, MERS and COVID-19: cytokine storm - the common denominator and the lessons to be learned","volume":"223","author":"Ryabkova","year":"2021","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib134","first-page":"CD014962","article-title":"Remdesivir for the treatment of COVID-19","volume":"1","author":"Grundeis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.ccm.2025.12.018_bib135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ccm.2025.12.018_bib136","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"issue":"164","key":"10.1016\/j.ccm.2025.12.018_bib137","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0274-2021","article-title":"Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell","volume":"31","author":"Girkin","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"6515","key":"10.1016\/j.ccm.2025.12.018_bib138","first-page":"370","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"6515","key":"10.1016\/j.ccm.2025.12.018_bib139","first-page":"370","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib140","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/irv.12094","article-title":"Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year","volume":"7","author":"Bennett","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.ccm.2025.12.018_bib141","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00364-22","article-title":"Effective interferon lambda treatment regimen to control lethal MERS-CoV infection in mice","volume":"96","author":"Dijkman","year":"2022","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib142","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 - interim WHO solidarity trial results","volume":"384","author":"Consortium","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib143","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10238","key":"10.1016\/j.ccm.2025.12.018_bib144","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2025.12.018_bib146","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/mi.2016.107","article-title":"IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia","volume":"10","author":"Aoyagi","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"43","key":"10.1016\/j.ccm.2025.12.018_bib147","doi-asserted-by":"crossref","first-page":"26885","DOI":"10.1073\/pnas.2004688117","article-title":"Poxvirus-encoded TNF receptor homolog dampens inflammation and protects from uncontrolled lung pathology during respiratory infection","volume":"117","author":"Al Rumaih","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib148","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01870-2021","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Patel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2025.12.018_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2137","article-title":"Statin use and risk of community acquired pneumonia in older people: population based case-control study","volume":"338","author":"Dublin","year":"2009","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib151","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","article-title":"Statins: a viable candidate for host-directed therapy against infectious diseases","volume":"19","author":"Parihar","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib152","doi-asserted-by":"crossref","DOI":"10.1186\/cc13828","article-title":"Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies","volume":"18","author":"Wan","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ccm.2025.12.018_bib153","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fimmu.2020.00910","article-title":"Mycobacterium tuberculosis infection-driven foamy macrophages and their implications in tuberculosis control as targets for host-directed therapy","volume":"11","author":"Shim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ccm.2025.12.018_bib154","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3389\/fmicb.2019.02097","article-title":"Simvastatin enhances the immune response against mycobacterium tuberculosis","volume":"10","author":"Guerra-De-Blas","year":"2019","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.31083\/ph.2013.2745","article-title":"Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats","volume":"68","author":"Ma","year":"2013","journal-title":"Pharmazie"},{"issue":"6","key":"10.1016\/j.ccm.2025.12.018_bib156","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dkw014","article-title":"Statin adjunctive therapy shortens the duration of TB treatment in mice","volume":"71","author":"Dutta","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib157","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5588\/ijtld.22.0548","article-title":"Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial","volume":"27","author":"Adewole","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ccm.2025.12.018_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-10-152","article-title":"Statins in candidemia: clinical outcomes from a matched cohort study","volume":"10","author":"Forrest","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.ccm.2025.12.018_bib159","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1111\/j.1439-0507.2010.01957.x","article-title":"Case\u2013control study of statin prevention of mould infections","volume":"54","author":"Thompson","year":"2011","journal-title":"Mycoses"},{"issue":"2","key":"10.1016\/j.ccm.2025.12.018_bib160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13693786.2012.692490","article-title":"Candidemia outcomes not improved with statin use","volume":"51","author":"Welch","year":"2013","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.ccm.2025.12.018_bib161","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MAJ.0b013e31828318e2","article-title":"The effect of statin therapy on the incidence of infections: a retrospective cohort analysis","volume":"347","author":"Magulick","year":"2014","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.ccm.2025.12.018_bib162","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccm.2024.10.003","article-title":"Host-directed adjunctive therapies in immunocompromised patients with pneumonia","volume":"46","author":"Hensley","year":"2025","journal-title":"Clin Chest Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523125001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523125001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:43:30Z","timestamp":1779997410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523125001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":162,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0272523125001200"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2025.12.018","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}